Aclaris Therapeutics, Inc. (ACRS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACRS POWR Grades
- ACRS scores best on the Growth dimension, with a Growth rank ahead of 60.92% of US stocks.
- ACRS's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- ACRS ranks lowest in Momentum; there it ranks in the 5th percentile.
ACRS Stock Summary
- Aclaris Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 11.5% of US listed stocks.
- With a price/sales ratio of 136.2, Aclaris Therapeutics Inc has a higher such ratio than 97.07% of stocks in our set.
- In terms of volatility of its share price, ACRS is more volatile than 98% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Aclaris Therapeutics Inc, a group of peers worth examining would be XAIR, APTX, CUE, FGEN, and ORGS.
- ACRS's SEC filings can be seen here. And to visit Aclaris Therapeutics Inc's official web site, go to www.aclaristx.com.
ACRS Price Target
For more insight on analysts targets of ACRS, see our ACRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $32.75 | Average Broker Recommendation | 1.2 (Strong Buy) |
ACRS Stock Price Chart Interactive Chart >
ACRS Price/Volume Stats
| Current price | $17.93 | 52-week high | $30.38 |
| Prev. close | $17.91 | 52-week low | $1.41 |
| Day low | $17.80 | Volume | 95,691 |
| Day high | $18.02 | Avg. volume | 1,881,171 |
| 50-day MA | $22.55 | Dividend yield | N/A |
| 200-day MA | $14.16 | Market Cap | 934.28M |
Aclaris Therapeutics, Inc. (ACRS) Company Bio
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing novel drugs to address unmet needs in dermatology. The company was founded in 2012 and is based in Malvern, Pennsylvania.
Latest ACRS News From Around the Web
Below are the latest news stories about Aclaris Therapeutics Inc that investors may wish to consider to help them evaluate ACRS as an investment opportunity.
Aclaris Therapeutics (ACRS) Gets a Buy Rating from H.C. WainwrightIn a report released today, Ram Selvaraju from H.C. The post Aclaris Therapeutics (ACRS) Gets a Buy Rating from H.C. Wainwright appeared first on Smarter Analyst . |
Analysts Offer Insights on Healthcare Companies: Chinook Therapeutics (KDNY), Aclaris Therapeutics (ACRS) and Translate Bio (TBIO)Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Chinook Therapeutics (KDNY), Aclaris Therapeutics The post Analysts Offer Insights on Healthcare Companies: Chinook Therapeutics (KDNY), Aclaris Therapeutics (ACRS) and Translate Bio (TBIO) appeared first on Smarter Analyst . |
Aclaris Therapeutics secures $125M capital via equity raiseAclaris Therapeutics (ACRS) has priced its public offering of 7,042,254 common shares at $17.75/share, for expected gross proceeds of ~$125M.Underwriters' over-allotment is an additional 1,056,338 shares.Closing date is June 14. Jefferies, SVB Leerink and Piper Sandler are acting as joint book-running managers for the offering.Previously (June 8): Aclaris Therapeutics to... |
Hair Loss Treatment Market Is Booming Worldwide with Product development in future | Viviscal, Cipla Limited, Aclaris TherapeuticsThe global Hair Loss Treatment market which projected a CAGR of approximately +7% in the midst of the estimate time span of 2020-2027. Coherent Market Insights has added a new report to its database that qualifies an expressive and professional look |
Aclaris Announces Pricing of Public Offering of Common StockWAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 7,042,254 shares of its common stock at a price to the public of $17.75 per share. In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 1,056,338 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Aclaris are expected to be approximately $125.0 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters option. The offering i... |
ACRS Price Returns
| 1-mo | -20.52% |
| 3-mo | -20.38% |
| 6-mo | 135.61% |
| 1-year | 1,071.90% |
| 3-year | -7.53% |
| 5-year | -1.54% |
| YTD | 177.13% |
| 2020 | 242.33% |
| 2019 | -74.42% |
| 2018 | -70.03% |
| 2017 | -9.14% |
| 2016 | 0.74% |
Continue Researching ACRS
Want to see what other sources are saying about Aclaris Therapeutics Inc's financials and stock price? Try the links below:Aclaris Therapeutics Inc (ACRS) Stock Price | Nasdaq
Aclaris Therapeutics Inc (ACRS) Stock Quote, History and News - Yahoo Finance
Aclaris Therapeutics Inc (ACRS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...